logo-loader
viewMedlab Clinical Ltd

Medlab Clinical in trading halt with placement announcement imminent

The company’s securities will remain halted until Tuesday, December 17 or when an announcement is released to the market.

Medlab Clinical Ltd - Medlab Clinical in trading halt pending placement news
Medlab is developing therapies for pain management, depression and obesity

Medlab Clinical Ltd (ASX:MDC) has an announcement pending in relation to a placement and has been granted a trading halt by the ASX.

The trading halt will remain in place until the beginning of normal trade on Tuesday, December 17, 2019, or when an announcement is released to the market, whichever occurs earliest.

Medlab's securities last traded at 32.5 cents and the company has a market cap of approximately $70 million.

UK distribution agreement 

The company recently executed a distribution agreement with nutritional supplement manufacturer Cultech Ltd that will see Medlab expand its nutraceutical business into the UK.

This exclusive distribution agreement follows the recent execution of a definitive agreement to expand Medlab's nutraceutical business in the USA.

Similar to the US deal, the UK agreement provides minimal operating expenditure exposure for Medlab and provides for 20% royalties ex-factory under the transfer agreement.

Quick facts: Medlab Clinical Ltd

Price: 0.145 AUD

ASX:MDC
Market: ASX
Market Cap: $40.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read